Loading...
•
Dec 31, 2021
Tectonic Q4 2021 Earnings Report
AVROBIO reported financial results for Q4 and year ended Dec. 31, 2021, and provided a business update.
Key Takeaways
AVROBIO reported a net loss of $28.2 million for the fourth quarter of 2021. The company's cash runway is expected to last into Q1 2024.
Presented interim data from Phase 1/2 clinical trial of AVR-RD-04 in cystinosis at the 18th Annual WORLDSymposium™ 2022.
Dosed a third patient in our Phase 1/2 GUARD1 clinical trial in Gaucher disease type 1
Deprioritized Fabry disease program in January 2022 to focus pipeline on Gaucher disease programs, cystinosis, Hunter syndrome and Pompe disease programs, extending cash runway into the first quarter of 2024
Appointed Sean O’Bryan to chief regulatory officer in February 2022, Azadeh Golipour to chief technology officer in January 2022, and Essra Ridha to chief medical officer in October 2021.
Tectonic
Tectonic
Forward Guidance
AVROBIO plans to engage with regulatory agencies to discuss clinical development and regulatory strategy with the intent of initiating a company-sponsored clinical trial in 2023, subject to regulatory clearance.
Positive Outlook
- Plan to engage with regulatory agencies to discuss clinical development and regulatory strategy with the intent of initiating a company-sponsored clinical trial in 2023, subject to regulatory clearance for AVR-RD-04 in cystinosis.
- Plan to provide an interim clinical data update in 2022 for AVR-RD-02 in Gaucher disease type 1.
- Plan to engage with regulatory agencies on a Phase 2/3 clinical development strategy for AVR-RD-06 in Gaucher disease type 3.
- Subject to regulatory clearance, collaborators at the University of Manchester plan to initiate a Phase 1/2 clinical trial in 2023 for AVR-RD-05 in Hunter syndrome.
- Plan to engage with regulatory agencies on the clinical development strategy and plan to initiate a clinical trial in 2023, subject to regulatory clearance for AVR-RD-03 in Pompe disease.